Skip to main content
Category

Treatments

MEDPAGE TODAY
ResearchTreatments

New Options Challenge Standard Treatments in EGFR-Mutant NSCLC (MARIPOSA and MARIPOSA-2 Trials)

*October 2023* Take home message: In 1L setting, combo of Amivantamab (ami), an EGFR-MET bispecific antibody, and Lazertinib (laz), a CNS-penetrant 3rd-generation EGFR TKI, was evaluated against Osimertinib (osi) in the MARIPOSA study (NCT04487080) for treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC. After a median follow-up of 22.0 months, ami+laz…
laurabbook@gmail.com
December 24, 2023
PR Newswire
ResearchTreatments

Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

*September 2023* RARITAN, N.J., Sept. 28, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), in combination with lazertinib, an oral third-generation EGFR tyrosine kinase…
laurabbook@gmail.com
December 24, 2023
OBR Oncology
ResearchTreatments

Are New NSCLC Findings Practice Changing, or Is PFS Boost Not Enough?

*October 2023* Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data…
laurabbook@gmail.com
December 24, 2023
MEDPAGE TODAY
ResearchTreatments

Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

*September 2023* SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful and durable efficacy" in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to the phase II HERTHENA-Lung01 trial. Among the…
laurabbook@gmail.com
December 24, 2023
ResearchTreatments

Clinician Spotlight: Dr. Josh Reuss

*October 2023* This month we have the honor of featuring Dr. Josh Reuss, Assistant Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center Washington, DC. Dr. Reuss participated in the 2021 EGFR Resisters Research Summit and was a ‘Breakout Session’ winner for his research on A Phase II Open-label Study…
laurabbook@gmail.com
December 24, 2023
Springer Link
ResearchTreatments

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

*September 2023* This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small…
laurabbook@gmail.com
December 24, 2023
Onc Live
ResearchTreatments

FDA Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

*August 2023* A supplemental biologics license application (sBLA) seeking the expanded approval of amivantamab-vmjw (Rybrevant) in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations has been submitted to the FDA.1  …
laurabbook@gmail.com
September 29, 2023